The estimated Net Worth of Michael Rosenblatt is at least $791 millier dollars as of 12 November 2021. Michael Rosenblatt owns over 2,831 units of Rubius Therapeutics Inc stock worth over $419 and over the last 15 years he sold RUBY stock worth over $481,502. In addition, he makes $309,285 as Independent Director at Rubius Therapeutics Inc.
Sign up
Michael Rosenblatt RUBY stock SEC Form 4 insiders trading
Michael has made over 6 trades of the Rubius Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 2,831 units of RUBY stock worth $323,102 on 12 November 2021.
The largest trade he's ever made was exercising 15,000 units of Rubius Therapeutics Inc stock on 19 February 2013 worth over $1,245. On average, Michael trades about 1,230 units every 123 days since 2010. As of 12 November 2021 he still owns at least 5,051 units of Rubius Therapeutics Inc stock.
You can see the complete history of Michael Rosenblatt stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Rosenblatt biography
Dr. Michael Rosenblatt is Independent Director of the Company. Dr. Rosenblatt serves on the board of directors of Brooks Automation Inc. and has served on the boards of directors of Radius Health, Inc. and ProScript. Dr. Rosenblatt received an M.D. from Harvard Medical School and an A.B. in chemistry from Columbia University. Rosenblatt's extensive medical and scientific knowledge and his experience in clinical development and executive management in the pharmaceutical industry qualify him to serve as a member of our board of directors.
What is the salary of Michael Rosenblatt?
As the Independent Director of Rubius Therapeutics Inc, the total compensation of Michael Rosenblatt at Rubius Therapeutics Inc is $309,285. There are 13 executives at Rubius Therapeutics Inc getting paid more, with Pablo Cagnoni having the highest compensation of $1,721,130.
How old is Michael Rosenblatt?
Michael Rosenblatt is 69, he's been the Independent Director of Rubius Therapeutics Inc since 2014. There are no older and 18 younger executives at Rubius Therapeutics Inc.
What's Michael Rosenblatt's mailing address?
Michael's mailing address filed with the SEC is C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.
Insiders trading at Rubius Therapeutics Inc
Over the last 6 years, insiders at Rubius Therapeutics Inc have traded over $2,165,279 worth of Rubius Therapeutics Inc stock and bought 305,000 units worth $6,624,680 . The most active insiders traders include Noubar Afeyan, Roger Pomerantz et Robert Langer. On average, Rubius Therapeutics Inc executives and independent directors trade stock every 51 days with the average trade being worth of $2,709. The most recent stock trade was executed by Dannielle Appelhans on 24 February 2023, trading 10,385 units of RUBY stock currently worth $1,350.
What does Rubius Therapeutics Inc do?
developing a novel enucleated cell (ecell)(tm) therapy platform for unmet medical needs. founded by flagship venturelabs.
What does Rubius Therapeutics Inc's logo look like?
Complete history of Michael Rosenblatt stock trades at Brooks Automation, Merck & Co Inc, Rubius Therapeutics Inc et Axcella Health Inc
Rubius Therapeutics Inc executives and stock owners
Rubius Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Pablo Cagnoni,
President, Chief Executive Officer, Director -
Maiken Keson-Brookes,
Chief Legal Officer, Corporate Secretary -
Dr. Pablo J. Cagnoni M.D., Ph.D.,
CEO, Pres & Director -
David Epstein,
Chairman of the Board -
Laurence A. Turka M.D.,
Chief Scientific Officer and Head of Research & Translational Medicine -
Natalie Holles,
Independent Director -
David R. Epstein B.Sc., M.B.A.,
Exec. Chairman -
Dannielle Appelhans,
Chief Operating Officer -
Anne Prener,
Independent Director -
Jonathan Symonds,
Independent Director -
Francis Cuss,
Independent Director -
Catherine Sohn,
Independent Director -
Noubar Afeyan,
Independent Director -
Michael Rosenblatt,
Independent Director -
Lori Melancon,
IR Contact Officer -
Christina Coughlin,
Chief Medical Officer -
Greg ..,
Chief Quality Officer -
Laurence Turka,
Chief Scientific Officer -
Kris Elverum,
Senior Vice President - Business Development and Strategy -
Jose Carmona,
Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer -
Jill Murray,
VP & Head of HR -
Marissa Hanify,
Director of Corp. Communications -
Maiken Keson-Brookes,
Chief Legal Officer & Corp. Sec. -
Elhan Webb C.F.A.,
VP of Investor Relations -
Mark J. Hernon,
Chief Information Officer -
Spencer Fisk,
Sr. VP & Chief Technical Operations Officer -
Jose I. Carmona,
CFO, Principal Accounting Officer & Treasurer -
Ventures Fund Iv General Pa...,
-
Susanne Schaffert,
Director -
Robert Langer,
Director -
Roger Pomerantz,
Director -
Ventures Fund Iv General Pa...,
-
Torben Straight Nissen,
President -
Christopher L. Carpenter,
Chief Medical Officer -
Dannielle Appelhans,
CEO and President